+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety and tolerability of a second dose of the RSVpreF vaccine given during later pregnancies and to study how long immunity lasts from a single dose administered during a previous pregnancy. The study includes pregnant participants and their unborn babies as well as nonpregnant participants who previously received the vaccine. It is a Phase 3 trial focusing on prevention of RSV infection. Pregnant participants are divided into two groups those with previous antibody data who will receive a second dose of RSVpreF, and those without such data who will be randomly assigned to receive either RSVpreF or a placebo. Infants born to these participants will be monitored for safety and antibody levels up to six months after birth. Nonpregnant participants who received RSVpreF during an earlier pregnancy will have blood samples taken to assess the persistence of their immune response but will not receive any vaccine during this study. Participants will undergo safety assessments including monitoring for local and systemic reactions, adverse events, and serious adverse events after vaccination. Infant safety and antibody levels will also be closely observed. Blood samples will measure neutralizing antibodies at birth and at three and six months. The study involves informed consent and follows participants through pregnancy, birth, and postnatal periods up to six months for infants, with the total study duration extending to February 2028.

Age: 0Years +All GendersPhase 3
97 locations
L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.

Age: 18Years +FEMALEPhase 3
120 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying how well tilrekimig works and how safe it is when combined with medicated creams or ointments in adults and adolescents aged 12 years or older who have moderate to severe atopic dermatitis, also known as eczema. This common skin condition causes dry, itchy, red, and irritated skin. The study focuses on participants who have had atopic dermatitis for at least 12 months and have not responded well to standard topical treatments. Participants will be randomly assigned in a 21 ratio to receive either tilrekimig or a placebo through subcutaneous injections over a 20-week period. The study treatment period lasts 24 weeks, with the last dose given at week 20. After completing this phase, some participants may join a long-term extension study to continue monitoring the effects and safety of tilrekimig, while others will enter a 12-week safety follow-up ending 16 weeks after their last dose. During the study, participants will be monitored closely with evaluations including eczema severity assessments, quality of life questionnaires, and safety checks such as vital signs and laboratory tests. Researchers will measure outcomes like the proportion of participants showing improvement in eczema severity at week 16. The total participation time includes the treatment period and follow-up, lasting several months to assess both short-term and longer-term effects of the study medicine.

Age: 12Years +All GendersPhase 3
21 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations
R

Actively Recruiting

Researchers are evaluating a personalized cardiac pacing approach for patients with symptomatic heart failure with preserved ejection fraction HFpEF, where left ventricular ejection fraction is 50% or higher. This interventional, randomized, controlled, double-blinded study aims to compare the safety and effectiveness of dual chamber personalized pacing versus minimal or no pacing in improving heart failure symptoms and health status. Participants will have a qualifying Medtronic dual chamber pacemaker implanted. After implantation and before hospital discharge, they will be randomly assigned to either the treatment group, which receives personalized dual chamber pacing based on their height and baseline LVEF, or the control group, which receives minimal ventricular pacing at a non-personalized rate. Follow-up includes visits at 2, 6, and 12 months, after which the control group will switch to personalized pacing. Additional visits occur at 14, 18, and 24 months, followed by annual long-term monitoring until study completion. During the study, participants will undergo data collection at scheduled visits involving assessments of cardiovascular events, heart failure status using quality of life questionnaires, six-minute walk tests, and blood markers like NT-proBNP. Safety will be monitored for major complications related to the device or procedures for 12 months post-implant. The total participation spans approximately 4.5 years with enrollment over 24 months and follow-up of at least 18 months.

Age: 40Years +All GendersPhase Not Applicable
55 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to study a behavioral health prevention program called Journey of Hope-C19 JoH-C19, designed for racial and ethnic minority children living in low-income communities who have been affected by both the COVID-19 pandemic and recent climate-related disasters like hurricanes. The study focuses on preventing mental and behavioral health problems in children from 3rd to 8th grade who are at risk due to these overlapping challenges. The trial seeks to understand how well JoH-C19 works compared to an attention control program and to explore factors that influence its effects and implementation. The study randomly assigns about 800 children to one of two group programs JoH-C19 or a control program called Switch Off Get Active. Both programs involve eight 1-hour group sessions for children, delivered during school or after-school, with groups of 8 children each. Caregivers also participate in a 1.5-hour workshop before the childrens sessions begin. JoH-C19 focuses on disaster-related behavioral health prevention, while the control program covers healthy lifestyle topics. Participants will be assessed before the intervention and then at 2, 8, and 14 months after starting the program using questionnaires that measure behavioral and emotional symptoms, coping skills, social relationships, academic performance, and family functioning. The research also looks at how stress related to COVID-19 affects outcomes and gathers feedback on how the programs are delivered in schools and community settings. The total study period allows for observing both short- and longer-term effects of the interventions.

Age: 8Years - 14YearsAll GendersPhase Not Applicable
9 locations
L

Actively Recruiting

Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.

All AgesAll Genders
338 locations

1-10 of 13

1